BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 1640725)

  • 1. Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.
    Dhingra K; Kurzrock R; Kantarjian H; Baine R; Eastman PS; Ku S; Gutterman JU; Talpaz M
    Leukemia; 1992 Aug; 6(8):754-60. PubMed ID: 1640725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.
    Paschka P; Müller MC; Merx K; Kreil S; Schoch C; Lahaye T; Weisser A; Petzold A; König H; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Sep; 17(9):1687-94. PubMed ID: 12970765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
    Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
    Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
    J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon alpha/ara-C.
    Müller MC; Gattermann N; Lahaye T; Deininger MW; Berndt A; Fruehauf S; Neubauer A; Fischer T; Hossfeld DK; Schneller F; Krause SW; Nerl C; Sayer HG; Ottmann OG; Waller C; Aulitzky W; le Coutre P; Freund M; Merx K; Paschka P; König H; Kreil S; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
    Leukemia; 2003 Dec; 17(12):2392-400. PubMed ID: 14523462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
    Schulze E; Krahl R; Thalmeier K; Helbig W
    Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcr-abl-positive and -negative clonogenic cells in CML patients undergoing long-term interferon treatment.
    Wandl UB; Bützler R; Niederle N; Kloke O; Mengelkoch B; Becher R; Seeber S; Opalka B
    Leukemia; 1994 May; 8(5):776-9. PubMed ID: 7514245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants.
    Guerrasio A; Martinelli G; Saglio G; Rosso C; Zaccaria A; Rosti G; Testoni N; Ambrosetti A; Izzi T; Sessarego M
    Leukemia; 1992 Jun; 6(6):507-12. PubMed ID: 1602789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
    Hughes TP; Kaeda J; Branford S; Rudzki Z; Hochhaus A; Hensley ML; Gathmann I; Bolton AE; van Hoomissen IC; Goldman JM; Radich JP;
    N Engl J Med; 2003 Oct; 349(15):1423-32. PubMed ID: 14534335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of graft-versus-host disease on the eradication of minimal residual leukemia detected by polymerase chain reaction in chronic myeloid leukemia patients after bone marrow transplantation.
    Arnold R; Janssen JW; Heinze B; Bunjes D; Hertenstein B; Wiesneth M; Kubanek B; Heimpel H; Bartram CR
    Leukemia; 1993 May; 7(5):747-51. PubMed ID: 8483329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
    Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
    Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid quantitative detection of BCR-ABL transcripts in chronic myeloid leukemia patients by real-time reverse transcriptase polymerase-chain reaction using fluorescently labeled probes.
    Bolufer P; Sanz GF; Barragán E; Sanz MA; Cervera J; Lerma E; Senent L; Moreno I; Planelles MD
    Haematologica; 2000 Dec; 85(12):1248-54. PubMed ID: 11114130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection on BCR-ABL fusion gene in Ph1 chromosome positive leukemia by "nested" retrotranscriptase/polymerase chain reaction].
    Huang W; Cao Q; Lu Y
    Zhonghua Yi Xue Za Zhi; 1994 Nov; 74(11):662-5, 708. PubMed ID: 7866899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring the efficiency of interferon-alpha therapy in chronic myelogenous leukemia (CML) patients by competitive polymerase chain reaction.
    Hochhaus A; Lin F; Reiter A; Skladny H; Hehlmann R; Goldman JM; Cross NC
    Leukemia; 1997 Apr; 11 Suppl 3():541-4. PubMed ID: 9209451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of bcr-abl fusion transcripts following bone marrow transplantation for Philadelphia chromosome-positive leukemia.
    Kohler S; Galili N; Sklar JL; Donlon TA; Blume KG; Cleary ML
    Leukemia; 1990 Aug; 4(8):541-7. PubMed ID: 2201832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction.
    Lion T; Izraeli S; Henn T; Gaiger A; Mor W; Gadner H
    Leukemia; 1992 Jun; 6(6):495-9. PubMed ID: 1602787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Importance of quantitative evaluation of BCR-ABL transcripts using real-time PCR for effective treatment of chronic myeloid leukemia].
    Beránek M; Voglová J; Sýkorová A; Belada D; Bláha M
    Cas Lek Cesk; 2006; 145(1):25-9; discussion 29-30. PubMed ID: 16468238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible correlation between fusion pattern of BCR/ABL mRNA and clinical response to alpha-interferon in chronic myelogenous leukemia.
    Inoue T; Tojo A; Tsuchimoto D; Okamoto S; Ogura H; Tani K; Ozawa K; Shibuya M; Asano S
    Leukemia; 1992 Sep; 6(9):948-51. PubMed ID: 1518306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.